Time to Reconsider MEDIGENE AG (OTCMKTS:MDGEF) After More Short Sellers?

February 15, 2018 - By Migdalia James

The stock of MEDIGENE AG (OTCMKTS:MDGEF) registered an increase of 0.22% in short interest. MDGEF’s total short interest was 89,500 shares in February as published by FINRA. Its up 0.22% from 89,300 shares, reported previously.

It closed at $19.05 lastly. It is down 0.00% since February 15, 2017 and is . It has underperformed by 16.70% the S&P500.

Medigene AG, a biotechnology company, develops immunotherapy platforms to treat a range of cancers in various stages. The company has market cap of $442.42 million. It operates through two divisions, Immunotherapies and Other Products. It currently has negative earnings. The firm develops Dendritic cell vaccines in phase I/II clinical trials; and T-cell receptor-modified T cells and T-cell-specific monoclonal antibodies in preclinical development phase.

More notable recent Medigene AG (OTCMKTS:MDGEF) news were published by: Globenewswire.com which released: “Medigene announces outlicensing of AAVLP technology” on December 20, 2016, also Globenewswire.com with their article: “Medigene AG to be included in TecDAX Index” published on December 06, 2016, Globenewswire.com published: “Medigene appoints Dr. Thomas Taapken as Chief Financial Officer” on November 22, 2016. More interesting news about Medigene AG (OTCMKTS:MDGEF) were released by: Businesswire.com and their article: “bluebird bio and Medigene Establish Strategic T Cell Receptor (TCR) Alliance …” published on September 29, 2016 as well as Seekingalpha.com‘s news article titled: “Medigene AG: Addressing The CAR-T Market Pain Points” with publication date: March 18, 2015.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.